Considering the pT3 subset of ER+ BC patients (n = 06), only 1 (3.1%) patient presented with AR+ expression, whereas the majority of patients belonged to the pT1 (n = 17; 51.5%) and pT2 (n = 15; 45.4%) subgroups. This evidence concerns the gene ESR1 and breast cancer.